MuscleOnGLPHome/Research/August 25-31, 2026
Weekly research roundup
GLP-1 and muscle research: August 25-31, 2026
This week's papers span GLP-1 therapy in menopause, real-world body composition data on semaglutide, and emerging science on muscle-related pathways. A cross-sectional study on eating behavior and a rat-tissue study on exercise-incretin interactions round out the selection. As always, summaries reflect only what the abstracts report.
How to read this
- This roundup is compiled automatically from the abstracts of newly published research and is a neutral summary, not medical advice, not peer review, and not an endorsement. Studies vary in quality and preprints are not yet peer-reviewed. Read the linked source and talk to your clinician before changing anything.
Incretin-based therapies in peri- and postmenopausal women with obesity: an expert position statement from the Spanish Menopause Society.
This expert position statement from the Spanish Menopause Society synthesizes evidence on incretin-based therapies (including semaglutide and tirzepatide) in peri- and postmenopausal women with overweight or obesity. The authors note that semaglutide has the most direct menopause-specific evidence, though it remains limited and largely observational. The statement explicitly frames incretin therapy in this population within a 'cardiometabolic and functional framework' that incorporates skeletal muscle health, resistance exercise, adequate protein intake, fracture risk, and structured monitoring of functional and metabolic outcomes. The suggestion that concomitant hormone therapy may augment semaglutide-related weight loss is described as hypothesis-generating only.
Why it matters: This is a formal expert consensus document that places muscle health, protein intake, and resistance exercise at the center of GLP-1 care for a large and often under-studied population of women undergoing menopause.
What this means for you: This adds to the case for discussing skeletal muscle monitoring and protein intake goals with a clinician as part of a structured plan when using incretin therapies around menopause.
Longitudinal Changes in Body Composition, Adaptive Thermogenesis and Muscle Strength in Patients with Obesity Treated with Semaglutide.
This single-center retrospective observational study followed adults with obesity (without diabetes) for 12 months, comparing a lifestyle education program alone versus lifestyle plus semaglutide. The semaglutide group achieved significantly greater reductions in body weight, BMI, and waist circumference. However, bioelectrical impedance analysis showed that skeletal muscle mass and fat-free mass also decreased in the semaglutide group alongside fat mass reductions. The study used a standardized skeletal muscle index score validated against MRI data and also assessed resting energy expenditure and adaptive thermogenesis; the abstract notes the full results are not yet fully reported. The study is described as retrospective and observational, conducted at a single center.
Why it matters: This real-world observational study directly quantifies concurrent losses of both fat mass and skeletal muscle mass over 12 months of semaglutide treatment, underscoring the importance of tracking lean mass—not just total weight—during therapy.
What this means for you: This adds to the case for monitoring skeletal muscle mass and strength throughout semaglutide treatment, not just tracking the number on the scale.
Emerging Myostatin and Metabolic Hormone Pathway Modulators in Cardiometabolic Disease: Mechanisms, Evidence, and Therapeutic Potential.
This narrative review examines three emerging pathway modulators—myostatin (MSTN), fibroblast growth factor 21 (FGF21), and growth differentiation factor 15 (GDF15)—and their intersection with incretin biology in cardiometabolic disease including sarcopenic obesity. The abstract notes that myostatin inhibition increases lean body mass but has shown inconsistent functional benefits. GLP-1/GIP therapies are described as favorably influencing inflammation, fibrosis, and substrate utilization. The authors suggest that coordinated modulation of these pathways, guided by precision phenotyping and biomarker monitoring, may offer a more comprehensive approach to cardiometabolic remodeling.
Why it matters: The review directly addresses the myostatin pathway and its interaction with incretin biology in the context of sarcopenic obesity and lean mass, highlighting that increasing lean mass does not automatically translate to functional improvement.
What this means for you: This is one more reason to monitor not just weight but also functional strength measures when on GLP-1 therapy, as lean mass changes and functional outcomes do not always move together.
The Effects of Glucagon-Like Peptide-1 Receptor Agonists on Chemosensory Function and Ingestive Behavior.
This cross-sectional study of 79 adults with obesity compared chemosensory function and eating behavior across three groups: pre-GLP-1RA use, 1-month users, and 6-month users. Six-month users showed lower food noise scores, cue responsivity, cravings, food reward, and energy intake compared with pre-use controls. Sweet taste detection thresholds were higher in both GLP-1RA groups. Notably, protein intake did not differ significantly across groups, suggesting that the appetite-suppressing effects of GLP-1RAs did not selectively spare or increase protein consumption.
Why it matters: The finding that protein intake did not differ significantly across groups—despite overall reductions in energy intake and food reward—raises a practical concern about whether people on GLP-1 therapy are maintaining adequate protein consumption as total calories fall.
What this means for you: This is one more reason to be intentional about hitting a daily protein target, since reduced appetite and food reward on GLP-1 therapy do not appear to automatically preserve protein intake.
The effect of sex and endurance exercise training on the incretin signaling pathway in 17 rat tissues.
This animal study (Fischer 344 rats) used data from the Molecular Transducers of Physical Activity Consortium to map incretin receptor expression across 17 tissues and examined how 1–8 weeks of treadmill endurance training altered incretin-related signaling at epigenetic, transcript, and protein levels. Endurance training produced sex- and tissue-specific changes in incretin receptor expression, including downregulation of the glucagon receptor across adipose and adrenal tissues and regulation of the GIP receptor in brain and adrenal tissues. The authors suggest these findings may help explain synergistic effects of exercise and incretin-based therapies on weight management and metabolic health. Results are from a rat model and may not directly translate to humans.
Why it matters: This animal study provides mechanistic evidence that exercise actively remodels incretin receptor expression in a tissue- and sex-specific manner, suggesting a biological basis for why combining exercise with GLP-1 therapy may produce effects beyond either intervention alone.
What this means for you: This is one more reason to consider resistance and aerobic training as a complement to GLP-1 therapy, given emerging evidence that exercise may interact with incretin signaling pathways at the tissue level.
Turn the evidence into a plan
The MuscleOnGLP handbook
These studies point the same direction our guides already put into practice: resistance training and enough protein preserve muscle while you lose weight. The 30-page handbook is the full, cited protocol.
See the handbook — $5 →